Comparison research on insulin aspart combined with insulin detemir versus continuous subcutaneous insulin infusion (CSII) in newly diagnosed type 2 diabetic patients

Objective To evaluate the efficacy and safety of insulin aspart combined with insulin detemir versus insulin pump therapy for newly diagnosed type 2 diabetic patients.Methods All 94 newly diagnosed type 2 diabetic patients were randomized into two groups,one treated by insulin aspart before 3 meals combined with insulin detemir at bedtime(group A),and the another treated by insulin pump(group B).FPG,2 hPG,FC-P,2 hC-P,time of glycemic control,dosage of insulin,and incidence of hypoglycemia were observed at the baseline and the end of the trail.Results After a 2-week treatment,the levels of FPG and 2 hPG decreased significantly from baseline in the two groups,while there was no significant difference between the two groups in time of glycemic control,dosage of insulin,and incidence of hypoglycemia.The increment of levels of FC-P in two groups before treatment:(0.69±0.13) and(0.81±0.15),after treatment:(1.3±0.2) and(1.5±0.15) and 2 hC-P before treatment:(1.62±0.16) and(1.44±0.17),after treatment:(3.8±0.80) and(3.5±1.21) was significant in statistics(all P0.05).Conclusions For the newly diagnosed type 2 diabetic patients,treatment with insulin aspart combined with insulin detemir improves β-cell functions through a good glycemic control with the same efficacy and safety as insulin pump.